PUBLISHER: The Business Research Company | PRODUCT CODE: 1978118
PUBLISHER: The Business Research Company | PRODUCT CODE: 1978118
Artificial intelligence (AI) in omics studies involves applying advanced computational algorithms, such as machine learning and deep learning, to analyze and interpret the extensive and complex datasets produced in various omics fields. AI helps process large volumes of biological data like DNA, RNA, proteins, and metabolites to understand their interactions and impacts on health.
The main offerings of AI in omics studies include software and services. AI software for omics studies consists of computer programs and applications that utilize AI algorithms to analyze large-scale biological data. These technologies encompass platforms such as sequencing, epigenomics, proteomics, and metabolomics. They are used in various applications, including oncology, infectious diseases, neurology, cardiovascular diseases, and immunology. End users of these technologies include academic and research institutions, biopharmaceutical companies, and other organizations.
Tariffs have impacted the AI in omics studies market by increasing the cost of imported sequencing equipment, high performance computing hardware, and laboratory instruments. Research institutions in North America and Europe are most affected due to reliance on globally sourced technologies. Higher equipment costs have influenced project timelines and research budgets. Smaller laboratories face slower adoption of advanced AI tools. At the same time, tariffs are encouraging domestic manufacturing of research equipment. This is supporting long-term resilience of regional life sciences ecosystems.
The artificial intelligence (AI) in omics studies market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in omics studies market statistics, including artificial intelligence (AI) in omics studies industry global market size, regional shares, competitors with a artificial intelligence (AI) in omics studies market share, detailed artificial intelligence (AI) in omics studies market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in omics studies industry. This artificial intelligence (AI) in omics studies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The artificial intelligence (AI) in omics studies market size has grown exponentially in recent years. It will grow from $1.23 billion in 2025 to $1.67 billion in 2026 at a compound annual growth rate (CAGR) of 35.4%. The growth in the historic period can be attributed to growth of next generation sequencing technologies, expansion of bioinformatics tools, increasing availability of biological big data, early adoption of machine learning in genomics, rising investment in life science research.
The artificial intelligence (AI) in omics studies market size is expected to see exponential growth in the next few years. It will grow to $5.55 billion in 2030 at a compound annual growth rate (CAGR) of 35.0%. The growth in the forecast period can be attributed to increasing demand for precision medicine, advancements in deep learning algorithms, rising adoption of AI in drug discovery, expansion of cloud-based omics platforms, growing focus on personalized healthcare. Major trends in the forecast period include AI-powered multi-omics data integration, machine learning-based genomic interpretation, AI-driven protein structure prediction, automated omics data analytics platforms, predictive biomarker discovery.
The increasing demand for personalized medicine is expected to support the growth of artificial intelligence in the omics studies market going forward. Personalized medicine involves tailoring medical treatments to individual patient characteristics to improve effectiveness and reduce adverse effects by considering genetic, environmental, and lifestyle factors. The growing use of personalized medicine is driven by advancements in genomic research, improved diagnostic technologies, and data-driven healthcare approaches. AI in omics studies enhances personalized medicine by providing deeper insights into disease mechanisms, improving treatment precision, and supporting better patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared with six approvals in 2022. Therefore, the increasing demand for personalized medicine is contributing to the growth of artificial intelligence in omics studies.
Leading companies operating in the artificial intelligence in omics studies market are focused on developing advanced solutions, such as cloud-based platforms that utilize data federation, to enhance data sharing and collaboration across research institutions while enabling seamless integration and analysis of large-scale omics data from multiple sources and maintaining data privacy and security. Cloud-based platforms integrate diverse omics data types, including genomics, proteomics, and metabolomics, and apply machine learning algorithms to analyze datasets and generate insights. For example, in September 2023, DNAstack, a Canada-based biotechnology company, launched Omics AI, a software suite designed to accelerate omics research. Omics AI supports large datasets, delivers real-time analytics, and enables global collaboration among researchers. While this innovation significantly improves research efficiency, it also highlights the importance of addressing data privacy concerns and implementing robust cybersecurity measures to protect sensitive genetic information.
In September 2023, Renovaro Biosciences Ltd., a US-based biotechnology company, acquired Gedi Cune Intl Ltd. for an undisclosed amount. With this acquisition, Renovaro Biosciences aims to reshape the medical landscape by focusing on advanced regenerative therapies and innovative biotechnological solutions. Gedi Cune Intl Ltd. is a US-based company that provides advanced tools for managing and analyzing multi-omics data.
Major companies operating in the artificial intelligence (AI) in omics studies market are Amazon.com Inc. , Hitachi Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers AG, General Electric Company, Agilent Technologies Inc., Koninklijke Philips N.V., Dassault Systemes SA, Illumina Inc., Fujifilm Holdings Corporation, Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Canon Medical Systems Corporation, Bruker Corporation, Qiagen N.V., BGI Genomics Co Ltd., Takara Bio Inc., Elekta AB
North America was the largest region in the artificial intelligence in omics studies market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in omics studies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the artificial intelligence (AI) in omics studies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The artificial intelligence in omics studies market consists of revenues earned by entities by providing data integration services, predictive modeling, gene and protein expression analysis, and image analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in omics studies market also includes sales of machine learning platforms, deep learning frameworks, bioinformatics software, data visualization tools, and robotics and automation tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Artificial Intelligence (AI) In Omics Studies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses artificial intelligence (AI) in omics studies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for artificial intelligence (AI) in omics studies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence (AI) in omics studies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.